Mr. Aldrich is a co-founder and Partner of Longwood Fund. He has co-founded and helped to build several successful biotech companies including Vertex Pharmaceuticals (NASDAQ: VRTX), Sirtris Pharmaceuticals (NASDAQ: SIRT acquired by Glaxo in 2008), Concert Pharmaceuticals (NASDAQ: CNCE), where he serves as Chairman of the Board, and Longwood portfolio companies Alnara Pharmaceuticals (acquired by Eli Lilly in 2010), OvaScience (NASDAQ: OVAS), Verastem (NASDAQ: VSTM) and Axial Biotherapeutics. Mr. Aldrich also serves as Chairman of the Board of Directors at Longwood portfolio company KalVista Pharmaceuticals and is a Director of Longwood portfolio companies Mitobridge, Inc., Colorescience, Inc. and Renovia, Inc. Prior to co-founding Longwood, Mr. Aldrich was General Partner of RA Capital, a biotechnology investment fund he co-founded in 2001. Mr. Aldrich was a founding employee of Vertex where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to joining Vertex, Mr. Aldrich held several management positions at Biogen, Inc. Mr. Aldrich received his undergraduate degree from Boston College, and an MBA from the Amos Tuck School at Dartmouth College.